SEC Form 4 · accession 0001628280-26-042247
Bicara Therapeutics Inc. · BCAX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jake Simson
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 10, 2026 · 4:32 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002023658
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $20.56 | Jun 9, 2026 | A | 19,475 | A | — | Jun 9, 2036 | Common Stock | 19,475 | 19,475 | D |
Explanation of responses
- F1The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.
- F2Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund") and R.A. Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.